Fremanezumab Reduces Monthly Migraine Days in Chronic Migraine

Share this content:
This randomized, placebo-controlled, double-blind study lasted 12 weeks and included adults with chronic migraine.
This randomized, placebo-controlled, double-blind study lasted 12 weeks and included adults with chronic migraine.
The following article is part of conference coverage from the 2018 American Headache Society Annual Scientific Meeting in San Francisco, California. Neurology Advisor's staff will be reporting breaking news associated with research conducted by leading experts in neurology. Check back for the latest news from AHS 2018.

SAN FRANCISCO — Fremanezumab has shown efficacy in safely reducing monthly headache days in individuals with chronic migraine. This research was presented at the American Headache Society's 60th Annual Scientific Meeting, held June 28–July 1, 2018 in San Francisco, California.

This randomized, placebo-controlled, double-blind study lasted 12 weeks and included adults with chronic migraine (defined by at least 15 monthly headache days and at least 8 monthly migraine days). Patients were randomly assigned to monthly fremanezumab (675 mg dose at baseline and 225 mg at 4 and 8 weeks), quarterly fremanezumab (675 mg dose at baseline and placebo at 4 and 8 weeks), or placebo (placebo treatment at baseline, 4 weeks, and 8 weeks). 

Patients who received fremanezumab were more successful than placebo in achieving at least 50% reduction in headache days of moderate severity or greater each month (quarterly: 37.6%, monthly: 40.8% with fremanezumab vs 18.1% with placebo; P <.0001). Patients treated with fremanezumab were also more likely to achieve at least 75% (nominally significant) and 100% rates of response (P <.001 for both) compared with placebo. The fremanezumab groups also showed a greater rate of sustained response from weeks 4 through 12 than placebo (P <.01); migraine-day response rates were also similar to these. 

The researchers concluded that “[fremanezumab] treatment results in early, sustained, and clinically relevant response rates at different response thresholds in patients with chronic migraine.”

For more coverage of AHS 2018, click here.

Reference

Easo-Joseph S, Winner PK, Bigal ME, et al. Achievement of response with fremanezumab in the treatment of chronic migraine. Presented at: 2018 American Headache Society Annual Scientific Meeting, June 28-July 1, 2018; San Francisco, CA. Abstract 446665. 

You must be a registered member of Neurology Advisor to post a comment.

Upcoming Meetings

Sign Up for Free e-newsletters